Optimization of the perfusion circuit and its possible impact on the inflammatory response.

Although there has been a steady improvement in cardiopulmonary bypass (CPB) techniques since its early introduction, it is still associated with some morbidity. Further attenuation of bypass-related systemic inflammatory reaction demands multidisciplinary action because the basic physiopathology is complex and cannot be controlled by one approach alone. This is an overview of the literature. Introduction of “mini” CPB circuits makes it easier to compare perfusion outcomes between different centers. Indeed, these circuits have a comparable fluid dynamic characteristic and surface area. All of them have a hemocompatible coating, and the technique avoids return of the pleuropericardial aspirations into the systemic circulation. As a consequence, results are very comparable to those obtained by beating heart surgery. However, vascular access and the resultant change in flow pattern in the aorta still have a negative correlation with neurocognitive outcome. A better understanding of the delicate balance between fluid dynamics, foreign material, coagulation, and inflammation is still a major requirement, especially because recent research combining pharmacologic, surgical, and anesthesia techniques with perfusion techniques has shown attenuation of the inflammatory response sequelae. For example, a better neurologic outcome is achieved by combining separation of suction, reducing hemodilution, administration of high-dose aprotinin, and volatile anesthetics and alternative cannulation techniques. Further improvement of CPB requires more uniform CPB circuits with known characteristics. The design should be based on evidence-based medicine philosophy. Combined efforts should be made by anesthesiologists, perfusionists, and surgeons to attenuate contact activation, ischemia-reperfusion injury, blood-material interaction, cell damage, and neurocognitive outcome.

[1]  Gerhard Ziemer,et al.  Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators. , 2007, Journal of biomedical materials research. Part B, Applied biomaterials.

[2]  I. C. Tudor,et al.  The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.

[3]  B. Schorn,et al.  Intra‐ and extravascular volume status in patients undergoing mitral valve replacement: crystalloid vs. colloid priming of cardiopulmonary bypass , 2006, European journal of anaesthesiology.

[4]  M. Gladwin,et al.  Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. , 2005, The Journal of clinical investigation.

[5]  M. Borger,et al.  Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. , 2005, The Annals of thoracic surgery.

[6]  R. Habib,et al.  The independent effects of cardiopulmonary bypass hemodilutional anemia and transfusions on CABG outcomes. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  V. Rao,et al.  Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. , 2005, The Journal of thoracic and cardiovascular surgery.

[8]  K. Sun,et al.  The Effects of Pulsatile Flow Upon Renal Tissue Perfusion During Cardiopulmonary Bypass: A Comparative Study of Pulsatile and Nonpulsatile Flow , 2005, ASAIO journal.

[9]  R. Baker,et al.  Removal of glucose from the cardiopulmonary bypass prime: a prospective clinical audit. , 2004, The journal of extra-corporeal technology.

[10]  D. Haskard,et al.  Hemoglobin Scavenger Receptor CD163 Mediates Interleukin-10 Release and Heme Oxygenase-1 Synthesis: Antiinflammatory Monocyte-Macrophage Responses In Vitro, in Resolving Skin Blisters In Vivo, and After Cardiopulmonary Bypass Surgery , 2004, Circulation research.

[11]  E. Schmid,et al.  Preconditioning by Sevoflurane Decreases Biochemical Markers for Myocardial and Renal Dysfunction in Coronary Artery Bypass Graft Surgery: A Double-blinded, Placebo-controlled, Multicenter Study , 2003, Anesthesiology.

[12]  S. D. De Hert,et al.  Adding lactate to the prime solution during hypothermic cardiopulmonary bypass: a quantitative acid-base analysis. , 2003, British journal of anaesthesia.

[13]  G. Grillone,et al.  Haemolysis during cardiopulmonary bypass: how to reduce the free haemoglobin by managing the suctioned blood separately , 2001, Perfusion.

[14]  J. Pepper,et al.  Changes in aortic rotational flow during cardiopulmonary bypass studied by transesophageal echocardiography and magnetic resonance velocity imaging: a potential mechanism for atheroembolism during cardiopulmonary bypass , 2001, Heart and Vessels.

[15]  P. Biglioli,et al.  Cardiopulmonary bypass increases plasma bradykinin concentrations. , 1999, Immunopharmacology.

[16]  S. Noble,et al.  Aprotinin , 2012, Drugs.

[17]  G. V. Van Nooten,et al.  Hydrodynamical Comparison of Aortic Arch Cannulae , 1998, The International journal of artificial organs.

[18]  M. D. De Buyzere,et al.  Effect of haptoglobin on the metabolism of vitamin C. , 1997, The American journal of clinical nutrition.

[19]  R. Colman,et al.  Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. , 1996, Circulation.

[20]  W. van Oeveren,et al.  Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. , 1995, The Annals of thoracic surgery.